Korean J Dermatol.
2014 Jul;52(7):494-497.
Development of Renal Disorder in a Patient Receiving Infliximab (Remicade(R)) for Psoriasis
- Affiliations
-
- 1Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea. tykimder@catholic.ac.kr
Abstract
- Infliximab (Remicade(R)) has been used for treating many chronic inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and psoriasis. Complications such as infusion reaction and infection in infliximab therapy have been reported, but renal complications are rare. We present data on a patient with psoriasis for 15 years who developed new onset renal disorders (IgA nephropathy, acute tubulointerstitial nephritis, acute tubular necrosis) after treatment with infliximab (duration of therapy: 12 months, 8 times). Because the patient with psoriasis receiving infliximab may develop new onset renal disorders, we recommend the evaluation of renal function.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Infliximab: Effective Therapy for Pustular Psoriasis
- A Case of Infliximab-induced Psoriasis in Treatment of Ankylosing Spondylitis
- A Case of Recurrent Generalized Pustular Psoriasis Treated with a Combination of Infliximab with Methotrexate and Retinoid
- A Case of Pustular Psoriasis Developed during Infliximab Treatment for Crohn's Disease
- Repeated Paradoxical Aggravation of Preexisting Psoriasis during Infliximab Treatment for Crohn's Disease
